Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05931393 · ClinicalTrials.gov registry record · Phase 2

Sequential Treatment of Cabozantinib for Advanced Renal Cell Carcinoma (RCC)

A Phase 2 study of Renal Cell Carcinoma and RCC, sponsored by University of Texas Southwestern Medical Center.

Recruiting
Registry status
Phase 2
Development phase
18
Enrollment target
1
Study location

NCT05931393 is a Phase 2 study of Renal Cell Carcinoma and RCC that is actively recruiting participants, run by University of Texas Southwestern Medical Center. The registered enrollment target is 18 participants, below the 243-participant average among 121 other Renal Cell Carcinoma trials with a reported enrollment target (93% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05931393, a Phase 2 study of Renal Cell Carcinoma and RCC, is actively recruiting participants, sponsored by University of Texas Southwestern Medical Center.

RECRUITING
Registry status
Phase 2
Development phase
18 participants
Enrollment target
1
Study location

Study Summary

The goal of this clinical trial is to learn about the effects of a higher dose of ncabozantinib in patients with advanced renal cell carcinoma who have progressed on or after receiving cabozantinib treatment.

Conditions Studied

Renal Cell Carcinoma RCC

Interventions

  • DRUG Cabozantinib 80 MG

Study Locations (1)

Texas

  • UT Southwestern Medical Center - Dallas

Trial Details

FieldValue
Enrollment Target 18 participants
Start Date 2023-12-20
Est. Completion 2028-12-31
Phase Phase 2

Sponsor

University of Texas Southwestern Medical Center

837 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT05931393

The ClinicalTrials.gov registry entry for NCT05931393 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 243-participant average among 121 other Renal Cell Carcinoma trials with a reported enrollment target (93% lower). The listed sponsor is University of Texas Southwestern Medical Center, which has 837 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Renal Cell Carcinoma appearing as the primary indexed condition, and to 1 intervention - of which Cabozantinib 80 MG is the first listed.

NCT05931393 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.

Frequently Asked Questions

What is clinical trial NCT05931393 about?

NCT05931393 is a clinical study titled "Sequential Treatment of Cabozantinib for Advanced Renal Cell Carcinoma (RCC)". The goal of this clinical trial is to learn about the effects of a higher dose of ncabozantinib in patients with advanced renal cell carcinoma who have progressed on or after receiving cabozantinib treatment.

What is the current status of trial NCT05931393?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 18 participants. The study started on 2023-12-20. Estimated completion is 2028-12-31.

What conditions does trial NCT05931393 study?

This clinical trial studies the following conditions: Renal Cell Carcinoma, RCC.

What interventions are being tested in trial NCT05931393?

The interventions under investigation include: Cabozantinib 80 MG (DRUG).

Who is sponsoring clinical trial NCT05931393?

This trial is sponsored by University of Texas Southwestern Medical Center, which has 837 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05931393 being conducted?

This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Renal Cell Carcinoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Renal Cell Carcinoma

All registered trials for this condition

RCC

All registered trials for this condition

Texas

All trials with a study site in Texas

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.